COMPOSITIONS AND METHODS FOR TREATING HYDROGEN SULFIDE-MEDIATED HYPERDYNAMIC CIRCULATION

摘要

A pharmaceutical composition generally includes a compound that reduces H₂S in the gut of a subject and a pharmaceutically acceptable carrier. In some embodiments, the compound that reduces H₂S in the gut of a subject can include magnesium or a salt thereof, bismuth or a salt thereof, molybdenum or a salt thereof, zinc or a salt thereof, iron or a salt thereof, nickel or a salt thereof, nitrate or a salt thereof, cobinamide or a salt thereof, a heme protein, an antimicrobial, an antibiotic, a prebiotic, a probiotic, or a synbiotic.;In another aspect, a method of detecting H₂S-mediated hyperdynamic circulation, or a consequence thereof in a subject having, or at risk of having, H₂S-mediated hyperdynamic circulation generally includes obtaining a biological sample from the subject, measuring H₂S in the sample, and identifying the subject as having H₂S-mediated hyperdynamic circulation if the H₂S measured in the sample is greater than a predetermined threshold. In some embodiments, the biological sample can be plasma or blood. In some of these embodiments, the predetermined threshold is a plasma H₂S concentration of 45 μM. In other embodiments, the predetermined threshold is a baseline plasma H₂S concentration measured from a previous sample from the subject.